Erratum by unknown
Arsenic on the Hands of
Children
Kwon et al. (2004) reported significantly
elevated dislodgeable soluble arsenic loads
on (one or both?) hands of children follow-
ing play on structures treated with chro-
mated copper arsenate (CCA) but then
concluded that the observed difference is
unimportant: 
With a safe conservative assumption that all the
arsenic on children’s hands is ingested, the meas-
ured value is below the estimated average daily
intake of inorganic arsenic from water and
food ….
However, Kwon et al.’s analysis is not
conservative for at least two reasons. First, it is
likely that they substantially underestimated
arsenic on hands. Kwon et al. reported, but
apparently did not actually measure, total
arsenic on hands. They washed hands, fil-
tered the wash water, and measured soluble
arsenic in the filtrate. Insoluble residue was
measured as dry mass gain on the filters.
They then estimated insoluble arsenic on
hands as the product of the average arsenic
concentration in playground sand samples
(not solids recovered from hands) and filter
dry weight gain. I did not arrive at this con-
clusion because the procedures are clearly
described in the paper but because a) there
is no discussion of extraction of filters and
b) the ratios of minimum, mean, median,
and maximum “sand arsenic” on hands to
minimum, mean, median, and maximum
sand mass recovered from hands are nearly
constant and equivalent (in all cases but
one) to the mean concentration reported for
each playground. 
This procedure could easily give a very
poor estimate of insoluble arsenic on hands
because unfractionated 0- to 6-in sand sam-
ples are likely to be a poor surrogate for
adherent particles. The filter residue from
the hand-wash water probably contained at
least some wood particles with much higher
arsenic concentrations and lower densities
than the playground sand. Hemond and
Solo-Gabriele (2004) reviewed studies in
which (typically adult) human hands were
used to deliberately wipe CCA-treated lum-
ber and reported much higher arsenic
residues on hands than found by Kwon
et al. (2004). One obvious potential expla-
nation is that the arsenic concentration in
material dislodged from CCA-treated wood
(Nico et al. 2004) can easily be 1,000-fold
higher than the 2–3 ppm found by Kwon
et al. in playground sand. 
Second, the observed loads that Kwon
et al. (2004) reported may be greatly influ-
enced by the very activity they wish to
assess. That is, mass recoverable at any
given time reflects net accumulation and
does not include material already ingested.
Consider the following simplified model of
mass accumulation on hands:
A ×
dL
dt = G – (king × L × A),
where A = area (in square centimeters), L =
load (in milligrams per square centimeter),
G = net gain in the absence of ingestion
(addition minus losses other than ingestion;
in milligrams per hour), and king = a first
order rate constant describing ingestion (per
hour). 
At steady state,
0 = Gss – king × A × Lss
and 
A × Lss = Gss ÷ king.
Assuming reasonable efficiency of wash-
ing, Kwon et al. (2004) provided a measure
of the product of the two variables on the
left hand side (for soluble arsenic). They
have not measured either of the variables on
the right hand side. In the absence of
knowledge of king, they guessed. Because an
infinite number of paired values of G and
king can be selected to match the available
data, large values of king are not excluded.
Hence any reassuring conclusion based on
this work is a reflection of the assumed rate
at which hand residues are orally harvested
and not of the reported measurements.
Kwon et al. (2004) further concluded
that
Most of the arsenic on children’s hands is water
soluble and is readily washed off with water. We
recommend that children wash their hands after
playing to reduce their potential exposure to
arsenic.
Again, this conclusion is not supported by
evidence presented in the article. To evalu-
ate efficiency of washing, some measure of
the initial mass present is required. Kwon
et al. measured removable soluble arsenic
and estimated removable insoluble arsenic.
They did not measure or estimate either sol-
uble or insoluble arsenic remaining on the
hands. Because insoluble arsenic bound to
soil or wood is likely to be at least partially
removed mechanically by washing regardless
of solubilization, washing is probably a good
strategy. However, that argument is merely
logical rather than empirical and could have
been made in the absence of Kwon et al.’s
experiments. 
Kwon et al. (2004) stated that the pur-
pose of their study was to provide “direct
measurement of arsenic levels on the hands
of children in contact with … CCA-treated
wood ….” Given that arsenic is amenable to
biomonitoring via urine, comparable urine
samples from children who do and do not
play on CCA-treated structures are what is
most needed. Then perhaps we would be
able to stop guessing about ingestion rates.
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Arsenic on the Hands of
Children: Wang et al. Respond
In our study of arsenic on children’s hands
(Kwon et al. 2004), we measured arsenic in
water samples in which participating chil-
dren washed both hands after playing on
selected playgrounds. The hand-washing
water was filtered, and the soluble arsenic
concentration in the filtrate was deter-
mined by inductively coupled plasma mass
spectrometry. In response to Kissel’s com-
ment that we did not measure insoluble
arsenic, we analyzed the arsenic levels in
the insoluble residue collected on the filter
and summarized the unpublished data
here. Results from the analysis of 64 sam-
ples from the CCA playgrounds and
another 63 samples from the non-CCA
playgrounds are available upon request.
The total amount of arsenic in the insolu-
ble residue collected in the hand-washing
water of 64 children from the eight
CCA playgrounds was 418 ± 601 ng
(mean ±SD), compared to 172 ± 278 ng in
the hand-washing water of 63 children
from the eight non-CCA playgrounds. The
total arsenic collected in the hand-washing
water (insoluble arsenic on the filter plus
water-soluble arsenic in the filtrate) was
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265 ± 311 ng for the non-CCA play-
grounds. The maximum amount of total
arsenic collected from children’s hands was
4,743 ng (4.7 µg). This is compared with
the 3.9 µg that we reported previously
(Kwon et al. 2004). 
To provide a perspective of relative con-
tribution of this amount of arsenic to the
overall exposure to arsenic, in our article
(Kwon et al. 2004) we included references
for the average daily dietary ingestion of
total arsenic: 
38 µg (15 µg for children 1–4 years of age) for
Canada (Dabeka et al. 1993), 62 µg for the
United States (Gartrell et al. [1985]), 89 µg for
the United Kingdom (Food Additives and
Contaminants Committee 1984), 55 µg for New
Zealand (Dick et al. 1978), and 160–280 µg for
Japan (Tsuda et al. 1995). A range of arsenic
species that have different toxicities may be present
in food (Le et al. 2004). Estimated daily dietary
intake of inorganic arsenic was 8.3–14 µg in the
United States (Yost et al. 1998), 4.8–12.7 µg in
Canada (Yost et al. 1998), and 15–211 µg in
Taiwan (Schoof et al. 1998).
We did not monitor children’s hand-to-
mouth activity because this behavior has
already been documented in the literature
(Reed et al. 1999; Tulve et al. 2002). Our
intent was to provide direct measurements
of the amount of arsenic on children’s
hands. We recognize the importance of
these other studies, as we pointed out in our
“Conclusions” (Kwon et al. 2004): 
The results—along with other information, such
as the frequency and habit of hand-to-mouth
activity, efficiency of transfer of arsenic from
hands to mouth, and repeated contact of hands
with CCA-treated wood surface after hand-to-
mouth activity—are useful for assessing children’s
exposure to arsenic.
We have measured arsenic in sequen-
tial hand-washings and found that most
arsenic was present in the first hand-wash-
ing (unpublished data). Results of arsenic
in hand-washings of three children before
and after playing on a CCA playground
are available upon request. The amount of
arsenic in the second washing was < 10%
of that in the first washing, suggesting
that the arsenic on children’s hands is
readily washed off with water. Therefore,
we conclude that children should “wash
their hands after playing to reduce their
potential exposure to arsenic” (Kwon et al.
2004). 
Biomonitoring of arsenic species in
urine samples from children who play on
CCA-treated structures and children who
do not could be useful if the ingestion of
arsenic from dietary sources would not be a
major confounder. 
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Glyphosate Results Revisited
With respect to the recent article by De Roos
et al. (2005), we would like to a) comment
on the authors’ incomplete genotoxicity
review, which is inconsistent with conclu-
sions reached by regulatory agencies; b) esti-
mate the likely range of systemic doses and
margins of exposure for farmers based on
comprehensive glyphosate biomonitoring
data published in 2004; and c) request fur-
ther evaluation of confounding and selection
bias in their analyses for multiple myeloma.
In their discussion of genotoxicity, De
Roos et al. focused on selected studies that
conflict with the weight of evidence for
glyphosate and Roundup brand (Monsanto
Company, St. Louis, MO) agricultural her-
bicides containing glyphosate. They cited
Williams et al. (2000) regarding the lack of
a carcinogenic effect in rodent feeding stud-
ies with glyphosate but neglected to cite the
extensive genotoxicity review in the same
article in which Williams et al. concluded
that Roundup and its components do not
pose a risk for heritable or somatic mutations.
This conclusion is in agreement with find-
ings by the U.S. Environmental Protection
Agency (U.S. EPA 1993), the World Health
Organization (WHO 1994), the European
Commission (2002), and regulatory agencies
worldwide. None of the studies cited by
De Roos et al. (2005) as presumptive evi-
dence of genotoxicity were conducted under
Good Laboratory Practices or according to
international guidelines. Additionally, many
of these studies used toxic dose levels and/or
irrelevant routes of exposure.
When evaluating epidemiologic find-
ings, it can be helpful to compare the range
of likely exposure levels to the exposure lev-
els of toxicologic significance (Acquavella
et al. 2003). The cancer no-effect levels for
glyphosate, based on rat and mouse life-
time feeding studies, are 1,000 and 1,500
mg/kg/day, respectively (Williams et al.
2000). Acquavella et al. (2004) reported
results of a biomonitoring study in which
48 farmers collected all of their urine over
5 consecutive days (before, during, and for
3 days after a glyphosate application). In
this study, the maximum systemic dose
resulting from application of glyphosate to
areas as large as 400 acres was 0.004 mg/kg.
The geometric mean systemic dose was
0.0001 mg/kg. Accordingly, in the worst-
case situation, if a farmer made a similar
application every day for a lifetime, the sys-
temic dose would be at least 250,000-fold
lower than the cancer no-effect level in
rodents. Indeed, this very large margin of
exposure combined with the lack of evi-
dence for genotoxicity must be factored
into an assessment of biologic plausibility.
Finally, De Roos et al.’s Table 2
(De Roos et al. 2005) shows an age-adjusted
relative risk (RR) of 1.1 [95% confidence
interval (CI), 0.5–2.4] associating multiple
myeloma and ever-use of glyphosate. The
RR adjusted for selected demographic and
lifestyle variables was 2.6 (95% CI, 0.7–9.4).
The factors that account for the difference in
these RRs are not well explained. Given the
weak associations between the covariates and
ever-use of glyphosate and the weak or
nonexistent relation between these variables
and risk of multiple myeloma, it is unlikely
that the change in RR from 1.1 to 2.6 is
attributable to confounding. The authors
mention that only 75% of eligible subjects
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and that this reduction in analytic sample size
was due to the exclusion of subjects that were
missing covariate data. Further, De Roos
et al. (2005) did not find an association in the
complete data set without adjustment for
covariates (RR = 1.1), but they did find a
positive association in the restricted data set
without adjustment for covariates. The differ-
ence in association due simply to restricting
the data set to those with covariate informa-
tion was not quantified, although such quan-
tification would help the reader understand
what proportion of the change from 1.1 to
2.6 was attributable to adjustment for candi-
date confounders and what proportion was
due to selection of subjects with more com-
plete data. An analysis stratified by each
covariate individually should have allowed
the investigators to identify covariates for
which missing data and/or adjustment made
the biggest impact on the estimated RR. The
identity of these covariates would help the
reader weigh the potential for confounding
versus selection bias to explain the change in
RR from 1.1 to 2.6. Given that only 32 cases
of multiple myeloma were observed and as
few as 19 cases were included in some of the
analyses, the authors should have explored
the potential for the analysis of sparse data to
result in estimates biased away from the null
(e.g., see Greenland et al. 2000 for an exam-
ple involving conditional logistic regression).
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Glyphosate Results Revisited:
De Roos et al. Respond
The reaction of Farmer et al. regarding our
article on glyphosate exposure and cancer
incidence in the Agricultural Health Study
(AHS) (De Roos et al. 2005) is difficult to
understand given the tentative nature of our
conclusions. For the most part, we found no
associations with the cancers we studied, and
to quote from our abstract, 
Glyphosate exposure was not associated with can-
cer incidence overall or with most of the cancer
subtypes we studied. There was a suggested associ-
ation with multiple myeloma incidence that
should be followed up as more cases occur in the
AHS.
Despite the fact that we believe our presenta-
tion of the data was quite fair and included a
lengthy discussion of possible biases affecting
our results, several comments by Farmer
et al. necessitate a response.
Farmer et al. had several criticisms of our
review of the genotoxicity literature (De
Roos et al. 2005). Although the discussion of
the toxicity studies is interesting, these stud-
ies only serve as background information in
our article; the epidemiologic associations
between glyphosate exposure and cancer
incidence we observed are the empirical
result of our investigation. Criticisms of our
reference to the genotoxicity literature do
not, of course, alter the human data we pre-
sented. We stated in our article the conclu-
sion of the U.S. Environmental Protection
Agency (U.S. EPA 1993) and the World
Health Organization (1994) that glyphosate
is not mutagenic, but because that conclu-
sion focused on the active ingredient,
glyphosate, and not formulated products
such as Roundup (Monsanto Company,
St. Louis, MO), we also cited several studies
which show potentially greater toxic effects
of Roundup than glyphosate. Our article
(De Roos et al. 2005) does not purport to be
a comprehensive review of the toxicology lit-
erature, and because of space limitations
imposed by the journal, we did not discuss
several studies showing potentially toxic
effects of several glyphosate-based pesticide
products through disruption of cell-cycle
control mechanisms, which may be relevant
for cancer as well as noncancer health out-
comes (Marc et al. 2002, 2004).
The fact the some of the studies we cited
did not use Good Laboratory Practices is
irrelevant, because this system is used pri-
marily in analytical chemistry and contract
laboratories for routine support of pesticide
regulation, and is not required by any of the
principal funding agencies for research stud-
ies. Studies that are submitted to the U.S.
EPA to support applications for licensing
pesticides are required to meet specified
guidelines for record keeping, data reporting,
and protocol development. These Good
Laboratory Practices provide some assurance
that regulators can rely on the data they
review and give them the ability to perform
audits as needed. Investigators who perform
studies for research purposes are not required
to follow these structured practices, but
many may do so. Furthermore, it does not
follow that work done in labs that do not
strictly adhere to the U.S. EPA’s testing and
reporting requirements follow “bad” labora-
tory practices. Quality assurance for research
studies is provided by the peer-review process
and by replication. This is analogous to the
distinction between clinical laboratory tests
performed in the context of human research
and tests performed for diagnostic purposes.
In order for these tests to be covered by insur-
ers, they must be performed in laboratories
approved by the Clinical Laboratory
Improvement Amendments (CLIA 2005).
CLIA approval assures that the test results are
valid but does not address the underlying sci-
ence that led to the development of the test.
In their letter, Farmer et al. used expo-
sure information from a study by Acquavella
et al. (2004) in which biomonitoring of
farmers who applied glyphosate was used to
determine a maximum dose calculation. The
dose thresholds Farmer et al. cite as relevant
for carcinogenicity are from mouse and rat
models in which the active ingredient,
glyphosate, was tested in feeding studies
(Williams et al. 2000). Lower relevant doses
may apply for Roundup and other formu-
lated products containing glyphosate, or for
glyphosate products used in combination
with other active ingredients. In addition,
epidemiology can provide direct information
on the question of what happens in humans
from more relevant routes of exposure.
Some questions were raised about the pos-
sible associations we observed between
glyphosate and multiple myeloma concerning
the discrepancy between the age-adjusted rela-
tive risk of 1.1 [95% confidence interval (CI),
0.5–2.4] and the relative risk adjusted for
selected demographic and lifestyle variables of
2.6 (95% CI, 0.7–9.4) (De Roos et al. 2005).
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ancy may be due to confounding or the selec-
tion of subjects into the more restricted
analysis. This is plausible, and we discussed
these issues at length in our article. The associ-
ation only appeared within the subgroup with
complete data on all the covariates; even with-
out any adjustment, there was a 2-fold
increased risk of multiple myeloma associated
with glyphosate use among the smaller sub-
group with covariate data. We acknowledged
that this could be due to selection bias, effect
modification, or confounding within this sub-
group. We would point out, however, that
confounding can be both positive and nega-
tive. The type of analysis suggested by Farmer
et al., in which the data are stratified by each
covariate individually in order to identify
covariates for which missing data and/or
adjustment made the biggest impact on the
estimated relative risk, would be unreliable for
such a small number of cases. Each estimate
would be subject to small sample bias
(Greenland 2000), which was cited by
Farmer et al. as an issue with our overall esti-
mate for myeloma. The most reliable
approach will be to reanalyze the data after
more cases accumulate, both to assess
whether the association with myeloma per-
sists and to further evaluate confounding
and selection bias using a larger case group
to support analyses. Following up initial
observations with more comprehensive epi-
demiologic data from the AHS has been our
plan since the inception of the study.
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ERRATUM
In Figures 1, 2, and 3 of “Altered Profiles of Spontaneous Novelty Seeking, Impulsive Behavior, and Response to D-Amphetamine in Rats
Perinatally Exposed to Bisphenol A” by Adriani et al. [Environ Health Perspect 111:395-401 (2003)], results for oil controls and
bisphenol A (BPA)-treated rats were labeled incorrectly. The corrected figures are shown below. EHP apologizes for the errors.
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Figure 1. (A,B) Mean (± SE) percentage of time spent in the novel compartment by subjects of both
sexes on testing day (experiment 1). (C,D) Mean (± SE) activity rate, measured as number of line
crossings per minute, shown by subjects of both sexes in the novel compartment on testing day.
During the pretreatment period (days 1–3), subjects were familiarized to one compartment. On test-
ing day, animals were placed in the familiar compartment. After 5 min, a partition was removed and
subjects were allowed free access to a novel compartment of the apparatus for a 24-min session.
*p < 0.05 in comparisons between BPA and control perinatal treatments (n = 9).
Figure 2. Mean (± SE) choice (%) of the large rein-
forcer, demanded by nose poking at the LAD hole,
shown by rats during the test for impulsivity
(experiment 2). These data reveal that, as the
length of the delay increased, animals increased
demanding the small but immediate reinforce-
ment and decreased demanding the larger but
delayed one. A shift to the right of the whole
curve (i.e., a profile of reduced impulsivity) was
evident in BPA-exposed rats compared with con-
trols. In the absence of significant differences,
data from the two sexes were collapsed (n = 18).
Figure 3. Mean (± SE) frequency of inadequate responding at the IAS hole (i.e., nose poking during
the length of the delay, when it was without any consequence) shown by rats during the test for
impulsivity (experiment 2). These data reveal that, when animals were waiting for the delivery of
the large reinforcer, they failed to rest and were demanding the immediate one. A clear-cut
demasculinization in the restlessness profile was evident.
*p < 0.05 in multiple comparisons between BPA and control perinatal treatments (n = 9).